The role of depression and social support in non-fatal drug overdose among a cohort of injection drug users in a Canadian setting

Drug and Alcohol Dependence

Volumn 132, Issue 3, 2013, Pages 603-609

  Pabayo, Roman ^a   Alcantara, Carmela ^a,b   Kawachi, Ichiro ^a   Wood, Evan ^c,d   Kerr, Thomas ^c,d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b Department of Medicine   (United States)

^c ST PAUL S HOSPITAL   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Depression; Longitudinal data analysis; Social epidemiology; Social support; Substance use

Indexed keywords

COCAINE; DIAMORPHINE; METHADONE; MORPHINE;

ADULT; ARTICLE; BIRTHPLACE; CANADA; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DEPRESSION; DRUG OVERDOSE; FEMALE; HETEROSEXUALITY; HOMELESSNESS; HOMOSEXUALITY; HUMAN; INTRAVENOUS DRUG ABUSE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NON FATAL DRUG OVERDOSE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; SEXUAL ORIENTATION; SOCIAL SUPPORT; SYMPTOMATOLOGY;

DEPRESSION; LONGITUDINAL DATA ANALYSIS; SOCIAL EPIDEMIOLOGY; SOCIAL SUPPORT; SUBSTANCE USE;

ADOLESCENT; BRITISH COLUMBIA; CANADA; COHORT STUDIES; DEPRESSION; DRUG OVERDOSE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PROSPECTIVE STUDIES; SOCIAL SUPPORT; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 84883556923     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2013.04.007     Document Type: Article

References (50)

1. Aldao A., Nolen-Hoeksema S., Schweizer S. Emotion-regulation strategies across psychopathology: a meta-analytic review. Clin. Psychol. Rev. 2010, 30:217-237.
2. Antonucci T.C., Akiyama H. An examination of sex differences in social support among older men and women. Sex Roles 1987, 17:737-749.
3. Bolton J.M., Robinson J., Sareen J. Self-medication of mood disorders with alcohol and drugs in the National Epidemiologic Survey on Alcohol and Related Conditions. J. Affect. Disord. 2009, 115:367-375.
4. Callaly T., Trauer T., Munro L., Whelan G. Prevalence of psychiatric disorder in a methadone maintenance population. Aust. N.Z. J. Psychiatry 2001, 35:601-605.
5. Carlin J.B., Wolfe R., Brown C.H., Gelman A. A case study on the choice, interpretation and checking of multilevel models for longitudinal binary outcomes. Biostatistics 2001, 2:397-416.
6. Carver C.S., Scheier M.F., Weintraub J.K. Assessing coping strategies: a theoretically based approach. J. Pers. Soc. Psychol. 1989, 56:267-283.
7. Center for Disease Control Community-based opioid overdose prevention programs providing naloxone - United States, 2010. MMWR 2012, 61:101-105.
8. Christakis N.A., Fowler J.H. The collective dynamics of smoking in a large social network. New Engl. J. Med. 2008, 358:2249-2258.
9. Coffin P.O., Tracy M., Bucciarelli A., Ompad D., Vlahov D., Galea S. Identifying injection drug users at risk of nonfatal overdose. Acad. Emerg. Med. 2007, 14:616-623.
10. Cohen S. Social relationships and health. Am. Psychol. 2004, 59:676-684.
11. Cohen S., Lemay E.P. Why would social networks be linked to affect and health practices?. Health Psychol. 2007, 26:410-417.
12. Conner K.R., Pinquart M., Duberstein P.R. Meta-analysis of depression and substance use and impairment among intravenous drug users (IDUs). Addiction 2008, 103:524-534.
13. Darke S., Hall W. Heroin overdose: research and evidence-based intervention. J. Urban Health 2003, 80:189-200.
14. Darke S., Ross J., Lynskey M., Teesson M. Attempted suicide among entrants to three treatment modalities for heroin dependence in the Australian Treatment Outcome Study (ATOS): prevalence and risk factors. Drug Alcohol Depend. 2004, 73:1-10.
15. Darke S., Williamson A., Ross J., Teesson M. Non-fatal heroin overdose, treatment exposure and client characteristics: findings from the Australian treatment outcome study (ATOS). Drug Alcohol Rev. 2005, 24:425-432.
16. Diez-Roux A.V. Multilevel analysis in public health research. Annu. Rev. Public Health 2000, 21:171-192.
17. Flaherty J., Richman J. Gender differences in the perception and utilization of social support: Theoretical perspectives and an empirical test. Soc. Sci. Med. 1989, 28:1221-1228.
18. Havens J.R., Oser C.B., Knudsen H.K., Lofwall M., Stoops W.W., Walsh S.L., Leukefeld C.G., Kral A.H. Individual and network factors associated with non-fatal overdose among rural Appalachian drug users. Drug Alcohol Depend. 2011, 115:107-112.
19. Kerr T., Fairbairn N., Tyndall M., Marsh D., Li K., Montaner J., Wood E. Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users. Drug Alcohol Depend. 2007, 87:39-45.
20. Kerr T., Small W., Moore D., Wood E. A micro-environmental intervention to reduce the harms associated with drug-related overdose: evidence from the evaluation of Vancouver's safer injection facility. Int. J. Drug Policy 2007, 18:37-45.
21. Khantzian E.J. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am. J. Psychiatry 1985, 142:1259-1264.
22. Kliewer W., Lepore S.J., Broquet A., Zuba L. Developmental and gender differences in anonymous support-seeking: analysis of data from a community help line for children. Am. J Community Psychol. 1990, 333-339.
23. Latkin C.A., Hua W., Tobin K. Social network correlates of self-reported non-fatal overdose. Drug Alcohol Depend. 2004, 73:61-67.
24. Lepore S.J., Allen K.A., Evans G.W. Social support lowers cardiovascular reactivity to an acute stressor. Psychosom. Med. 1993, 55:518-524.
25. Mackesy-Amiti M.E., Donenberg G.R., Ouellet L.J. Prevalence of psychiatric disorders among young injection drug users. Drug Alcohol Depend. 2012, 124:70-78.
26. Marshall B.D., Milloy M.J., Wood E., Montaner J.S., Kerr T. Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. Lancet 2011, 377:1429-1437.
27. Milloy M.J., Kerr T., Mathias R., Zhang R., Montaner J.S., Tyndall M., Wood E. Non-fatal overdose among a cohort of active injection drug users recruited from a supervised injection facility. Am. J. Drug Alcohol Abuse 2008, 34:499-509.
28. Milloy M.J., Kerr T., Tyndall M., Montaner J., Wood E. Estimated drug overdose deaths averted by North America's first medically-supervised safer injection facility. PLoS ONE 2008, 3:e3351.
29. Neale J. Suicidal intent in non-fatal illicit drug overdose. Addiction 2000, 95:85-93.
30. Pfab R., Eyer F., Jetzinger E., Zilker T. Cause and motivation in cases of non-fatal drug overdoses in opiate addicts. Clin. Toxicol. 2006, 44:255-259.
31. Pilowsky D.J., Wu L.T., Burchett B., Blazer D.G., Ling W. Depressive symptoms, substance use, and HIV-related high-risk behaviors among opioid-dependent individuals: results from the Clinical Trials Network. Subst. Use Misuse 2011, 46:1716-1725.
32. Potvin S., Stip E., Roy J.Y. Schizophrenia and addiction: an evaluation of the self-medication hypothesis. L'Encephale 2003, 29:193-203.
33. Radloff L. The CES-D scale: A self-report depression scale for research in the general population. Appl. Psychol Meas. 1977, 1:385-401.
34. Raudenbush S., Bryk A. Hierarchical Linear Models: Applications and Data Analysis Methods 2002, Sage Publications, Thousand Oaks, CA.
35. Richer I., Bertrand K., Vandermeerschen J., Roy E. A prospective cohort study of non-fatal accidental overdose among street youth: the link with suicidal ideation. Drug Alcohol Rev. 2012, (Epub ahead of print).
36. Rossow I., Lauritzen G. Balancing on the edge of death: suicide attempts and life-threatening overdoses among drug addicts. Addiction 1999, 94:209-219.
37. Shumaker S.A., Hill D.R. Gender differences in social support and physical health. Health Psychol. 1991, 102-111.
38. Springer S.A. High rates of depressive symptomatology among injecting drug users in Saskatoon, Canada. Evid. Based Ment. Health 2012, 15:9.
39. Strathdee S.A., Palepu A., Cornelisse P.G., Yip B., O'Shaughnessy M.V., Montaner J.S., Schechter M.T., Hogg R.S. Barriers to use of free antiretroviral therapy in injection drug users. J. Am. Med. Assoc. 1998, 280:547-549.
40. Teesson M., Havard A., Fairbairn S., Ross J., Lynskey M., Darke S. Depression among entrants to treatment for heroin dependence in the Australian Treatment Outcome Study (ATOS): prevalence, correlates and treatment seeking. Drug Alcohol Depend. 2005, 78:309-315.
41. Tobin K.E., Latkin C.A. The relationship between depressive symptoms and nonfatal overdose among a sample of drug users in Baltimore, Maryland. J. Urban Health 2003, 80:220-229.
42. Turner H.A. Gender and social support - taking the bad with the good. Sex Roles 1994, 30:521-541.
43. Tyndall M.W., Currie S., Spittal P., Li K., Wood E., O'Shaughnessy M.V., Schechter M.T. Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS 2003, 17:887-893.
44. Umberson D., Crosnoe R., Reczek C. Social relationships and health behavior across the life course. Annu. Rev. Sociol. 2010, 36:139-159.
45. Vingoe L., Welch S., Farrell M., Strang J. Unintentional overdose among a treatment sample of injecting drug misusers: accident or suicidal behavior?. J. Subst. Use 1999, 4:88-91.
46. Weiss R.D., Griffin M.L., Mirin S.M. Drug abuse as self-medication for depression: an empirical study. Am. J. Drug Alcohol Abuse 1992, 18:121-129.
47. Wilson D.K., Kliewer W., Bayer L., Jones D., Welleford A., Heiney M., Sica D.A. The influence of gender and emotional versus instrumental support on cardiovascular reactivity in African-American adolescents. Ann. Behav. Med. 1999, 21:235-243.
48. Wood E., Hogg R.S., Bonner S., Kerr T., Li K., Palepu A., Guillemi S., Schechter M.T., Montaner J.S. Staging for antiretroviral therapy among HIV-infected drug users. J. Am. Med. Assoc. 2004, 292:1175-1177.
49. Wood E., Hogg R.S., Lima V.D., Kerr T., Yip B., Marshall B.D., Montaner J.S. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. J. Am. Med. Assoc. 2008, 300:550-554.
50. Wood E., Stoltz J.A., Montaner J.S., Kerr T. Evaluating methamphetamine use and risks of injection initiation among street youth: the ARYS study. Harm Reduct. J. 2006, 3:18.